发明名称 |
COMPOSITIONS FOR THE TREATMENT OF CNS-RELATED CONDITIONS |
摘要 |
The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine. |
申请公布号 |
US2016243058(A1) |
申请公布日期 |
2016.08.25 |
申请号 |
US201615142519 |
申请日期 |
2016.04.29 |
申请人 |
Adamas Pharmaceuticals, Inc. |
发明人 |
Went Gregory T.;Fultz Timothy J.;Meyerson Laurence R. |
分类号 |
A61K31/13;A61K31/445;A61K9/20;A61K9/00 |
主分类号 |
A61K31/13 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating a patient with a neurological condition, comprising orally administering to a human subject in need thereof:
(a) 22.5 mg to 30 mg memantine or a pharmaceutically acceptable salt thereof provided in a sustained release dosage form, wherein wherein said sustained release memantine provides a change in mean plasma concentration of memantine as a function of time (dC/dT) that is: (1) less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0-Tmax of the immediate release form of memantine; and (2) 2.1 ng/ml/hr or less, determined in a time period of 0 to 4 hours; wherein dC/dT is measured in a single-dose human PK study; and (b) a therapeutically effective amount of immediate release donepezil. |
地址 |
Emeryville CA US |